Exploring the readiness of the Irish healthcare system to adopt advanced therapies: a scoping review protocol.

IF 2.4 4区医学 Q4 CELL & TISSUE ENGINEERING Regenerative medicine Pub Date : 2024-01-01 Epub Date: 2024-07-16 DOI:10.1080/17460751.2024.2368352

Isabella Devine, Clarice O'Brien, David Mockler, Cormac Kennedy, Gerry Hughes, Martina Hennessy

引用次数: 0

Abstract

Aim: Advanced therapy medicinal products (ATMPs) are medicines for human use that are based on genes, tissues or cells. They offer groundbreaking new opportunities for the treatment of disease and injury. However, ATMP adoption requires adjustments to current clinical practices and frameworks. This study investigates the readiness of the Irish healthcare system to adopt licensed ATMPs. Materials & methods: Scoping review, guided by the preferred reporting items for systematic reviews and meta-analyses - scoping review extension. A systematic search of English articles from 2013 to 2023 (published and grey literature) will be conducted.Results: Findings will be presented via narrative summary, graphical and tabular formats.Discussion: Review findings will be discussed in the context of recommendations that will inform national policy and strategy on the adoption of ATMPs in Ireland.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

探索爱尔兰医疗系统采用先进疗法的准备情况：范围界定审查协议。

目的：先进治疗药物产品（ATMP）是基于基因、组织或细胞的人类用药。它们为治疗疾病和损伤提供了突破性的新机遇。然而，采用 ATMP 需要对当前的临床实践和框架进行调整。本研究调查了爱尔兰医疗系统采用获得许可的 ATMP 的准备情况。材料与方法：范围界定审查，以系统审查和荟萃分析的首选报告项目为指导--范围界定审查扩展。将对 2013 年至 2023 年的英文文章（已发表和灰色文献）进行系统检索。结果：研究结果将以叙述性摘要、图表和表格的形式呈现。讨论：将结合相关建议讨论综述结果，这些建议将为爱尔兰采用 ATMP 的国家政策和战略提供参考。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Regenerative medicine 医学-工程：生物医学

CiteScore

4.20

自引率

3.70%

发文量

审稿时长

6-12 weeks

期刊介绍： Regenerative medicine replaces or regenerates human cells, tissue or organs, to restore or establish normal function*. Since 2006, Regenerative Medicine has been at the forefront of publishing the very best papers and reviews covering the entire regenerative medicine sector. The journal focusses on the entire spectrum of approaches to regenerative medicine, including small molecule drugs, biologics, biomaterials and tissue engineering, and cell and gene therapies – it’s all about regeneration and not a specific platform technology. The journal’s scope encompasses all aspects of the sector ranging from discovery research, through to clinical development, through to commercialization. Regenerative Medicine uniquely supports this important area of biomedical science and healthcare by providing a peer-reviewed journal totally committed to publishing the very best regenerative medicine research, clinical translation and commercialization. Regenerative Medicine provides a specialist forum to address the important challenges and advances in regenerative medicine, delivering this essential information in concise, clear and attractive article formats – vital to a rapidly growing, multidisciplinary and increasingly time-constrained community. Despite substantial developments in our knowledge and understanding of regeneration, the field is still in its infancy. However, progress is accelerating. The next few decades will see the discovery and development of transformative therapies for patients, and in some cases, even cures. Regenerative Medicine will continue to provide a critical overview of these advances as they progress, undergo clinical trials, and eventually become mainstream medicine.

期刊最新文献

Proliferation and differentiation of Wharton's jelly-derived mesenchymal stem cells on prgf-treated hydrogel scaffold. ATMP clinical trials in the UK. Industry updates from the field of stem cell research and regenerative medicine in September 2024. Correction. Industry updates from the field of stem cell research and regenerative medicine in August 2024.